#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Recent Progress of Antiprotozoan Agents
2-1	4-10	Recent	abstract[2]	new[2]	_	_
2-2	11-19	Progress	abstract[2]	new[2]	_	_
2-3	20-22	of	abstract[2]	new[2]	_	_
2-4	23-36	Antiprotozoan	abstract[2]|abstract|person[4]	new[2]|new|new[4]	_	_
2-5	37-43	Agents	abstract[2]|person[4]	new[2]|new[4]	_	_

#Text=2.1 .
3-1	44-47	2.1	abstract	new	_	_
3-2	48-49	.	_	_	_	_

#Text=Anti-Giardiasis
4-1	50-65	Anti-Giardiasis	abstract	new	ana	6-1

#Text=Giardiasis is caused by the protozoan parasite G. intestinalis ( also known as G. lamblia or G. duodenalis ) .
5-1	66-76	Giardiasis	event	new	coref	7-1
5-2	77-79	is	_	_	_	_
5-3	80-86	caused	_	_	_	_
5-4	87-89	by	_	_	_	_
5-5	90-93	the	animal[9]	new[9]	_	_
5-6	94-103	protozoan	abstract|animal[9]	new|new[9]	coref	7-6
5-7	104-112	parasite	animal[9]	new[9]	_	_
5-8	113-115	G.	_	_	_	_
5-9	116-128	intestinalis	_	_	_	_
5-10	129-130	(	_	_	_	_
5-11	131-135	also	_	_	_	_
5-12	136-141	known	_	_	_	_
5-13	142-144	as	_	_	_	_
5-14	145-147	G.	_	_	_	_
5-15	148-155	lamblia	_	_	_	_
5-16	156-158	or	_	_	_	_
5-17	159-161	G.	_	_	_	_
5-18	162-172	duodenalis	_	_	_	_
5-19	173-174	)	_	_	_	_
5-20	175-176	.	_	_	_	_

#Text=It is also known by the common name “ beaver fever , ” because this infection was reported in campers who drank contaminated water that was inhabited by beavers .
6-1	177-179	It	abstract	giv	_	_
6-2	180-182	is	_	_	_	_
6-3	183-187	also	_	_	_	_
6-4	188-193	known	_	_	_	_
6-5	194-196	by	_	_	_	_
6-6	197-200	the	abstract[11]	new[11]	appos	6-10[13_11]
6-7	201-207	common	abstract[11]	new[11]	_	_
6-8	208-212	name	abstract[11]	new[11]	_	_
6-9	213-214	“	_	_	_	_
6-10	215-221	beaver	animal|abstract[13]	new|giv[13]	_	_
6-11	222-227	fever	abstract[13]	giv[13]	_	_
6-12	228-229	,	_	_	_	_
6-13	230-231	”	_	_	_	_
6-14	232-239	because	_	_	_	_
6-15	240-244	this	abstract[14]	new[14]	_	_
6-16	245-254	infection	abstract[14]	new[14]	_	_
6-17	255-258	was	_	_	_	_
6-18	259-267	reported	_	_	_	_
6-19	268-270	in	_	_	_	_
6-20	271-278	campers	person	new	_	_
6-21	279-282	who	_	_	_	_
6-22	283-288	drank	_	_	_	_
6-23	289-301	contaminated	substance[16]	new[16]	coref	11-14[0_16]
6-24	302-307	water	substance[16]	new[16]	_	_
6-25	308-312	that	_	_	_	_
6-26	313-316	was	_	_	_	_
6-27	317-326	inhabited	_	_	_	_
6-28	327-329	by	_	_	_	_
6-29	330-337	beavers	animal	new	_	_
6-30	338-339	.	_	_	_	_

#Text=Giardiasis is the most common protozoan infection in human beings , and it occurs in both developing and industrialized countries .
7-1	340-350	Giardiasis	abstract	giv	coref	7-3[20_0]
7-2	351-353	is	_	_	_	_
7-3	354-357	the	abstract[20]	giv[20]	ana	7-13[0_20]
7-4	358-362	most	abstract[20]	giv[20]	_	_
7-5	363-369	common	abstract[20]	giv[20]	_	_
7-6	370-379	protozoan	abstract|abstract[20]	giv|giv[20]	coref	10-14[35_0]
7-7	380-389	infection	abstract[20]	giv[20]	_	_
7-8	390-392	in	abstract[20]	giv[20]	_	_
7-9	393-398	human	abstract[20]|person[21]	giv[20]|new[21]	coref	26-27[137_21]
7-10	399-405	beings	abstract[20]|person[21]	giv[20]|new[21]	_	_
7-11	406-407	,	_	_	_	_
7-12	408-411	and	_	_	_	_
7-13	412-414	it	event	giv	ana	8-1
7-14	415-421	occurs	_	_	_	_
7-15	422-424	in	_	_	_	_
7-16	425-429	both	place[23]	new[23]	coref	11-7[39_23]
7-17	430-440	developing	place[23]	new[23]	_	_
7-18	441-444	and	place[23]	new[23]	_	_
7-19	445-459	industrialized	place[23]	new[23]	_	_
7-20	460-469	countries	place[23]	new[23]	_	_
7-21	470-471	.	_	_	_	_

#Text=Its global incidence is believed to range between 20 % – 60 % , with 2 % – 7 % incidence in industrialized nations .
8-1	472-475	Its	event|abstract[25]	giv|new[25]	coref|coref|coref|coref	8-19[30_25]|11-1[38_0]|8-19[30_25]|11-1[38_0]
8-2	476-482	global	abstract[25]	new[25]	_	_
8-3	483-492	incidence	abstract[25]	new[25]	_	_
8-4	493-495	is	_	_	_	_
8-5	496-504	believed	_	_	_	_
8-6	505-507	to	_	_	_	_
8-7	508-513	range	_	_	_	_
8-8	514-521	between	_	_	_	_
8-9	522-524	20	quantity[26]	new[26]	_	_
8-10	525-526	%	quantity[26]	new[26]	_	_
8-11	527-528	–	quantity[26]	new[26]	_	_
8-12	529-531	60	quantity[26]|quantity[27]	new[26]|new[27]	_	_
8-13	532-533	%	quantity[26]|quantity[27]	new[26]|new[27]	_	_
8-14	534-535	,	_	_	_	_
8-15	536-540	with	_	_	_	_
8-16	541-542	2	quantity[28]	new[28]	_	_
8-17	543-544	%	quantity[28]	new[28]	_	_
8-18	545-546	–	quantity[28]	new[28]	_	_
8-19	547-548	7	quantity[28]|quantity[29]|abstract[30]	new[28]|new[29]|giv[30]	_	_
8-20	549-550	%	quantity[28]|quantity[29]|abstract[30]	new[28]|new[29]|giv[30]	_	_
8-21	551-560	incidence	quantity[28]|abstract[30]	new[28]|giv[30]	_	_
8-22	561-563	in	quantity[28]|abstract[30]	new[28]|giv[30]	_	_
8-23	564-578	industrialized	quantity[28]|abstract[30]|place[31]	new[28]|giv[30]|new[31]	_	_
8-24	579-586	nations	quantity[28]|abstract[30]|place[31]	new[28]|giv[30]|new[31]	_	_
8-25	587-588	.	_	_	_	_

#Text=Giardia intestinalis
9-1	589-596	Giardia	abstract	new	coref	14-4
9-2	597-609	intestinalis	_	_	_	_

#Text=was first described in 1681 after the Dutch microscopist Antonie van Leeuwenhoek observed the protozoan in his own diarrheic stools .
10-1	610-613	was	_	_	_	_
10-2	614-619	first	_	_	_	_
10-3	620-629	described	_	_	_	_
10-4	630-632	in	_	_	_	_
10-5	633-637	1681	time	new	_	_
10-6	638-643	after	_	_	_	_
10-7	644-647	the	person[34]	giv[34]	ana	10-17[0_34]
10-8	648-653	Dutch	person[34]	giv[34]	_	_
10-9	654-666	microscopist	person[34]	giv[34]	_	_
10-10	667-674	Antonie	person[34]	giv[34]	_	_
10-11	675-678	van	person[34]	giv[34]	_	_
10-12	679-690	Leeuwenhoek	person[34]	giv[34]	_	_
10-13	691-699	observed	_	_	_	_
10-14	700-703	the	abstract[35]	giv[35]	_	_
10-15	704-713	protozoan	abstract[35]	giv[35]	_	_
10-16	714-716	in	_	_	_	_
10-17	717-720	his	person|object[37]	giv|new[37]	_	_
10-18	721-724	own	object[37]	new[37]	_	_
10-19	725-734	diarrheic	object[37]	new[37]	_	_
10-20	735-741	stools	object[37]	new[37]	_	_
10-21	742-743	.	_	_	_	_

#Text=This disease is often prevalent in poor countries and communities that have untreated water , inadequate sanitation , and poor dietary status .
11-1	744-748	This	abstract[38]	giv[38]	coref	12-1[45_38]
11-2	749-756	disease	abstract[38]	giv[38]	_	_
11-3	757-759	is	_	_	_	_
11-4	760-765	often	_	_	_	_
11-5	766-775	prevalent	_	_	_	_
11-6	776-778	in	_	_	_	_
11-7	779-783	poor	place[39]	giv[39]	_	_
11-8	784-793	countries	place[39]	giv[39]	_	_
11-9	794-797	and	place[39]	giv[39]	_	_
11-10	798-809	communities	place[39]|organization	giv[39]|new	_	_
11-11	810-814	that	place[39]	giv[39]	_	_
11-12	815-819	have	place[39]	giv[39]	_	_
11-13	820-829	untreated	place[39]	giv[39]	_	_
11-14	830-835	water	place[39]|substance	giv[39]|giv	coref	12-19[50_0]
11-15	836-837	,	place[39]	giv[39]	_	_
11-16	838-848	inadequate	place[39]|substance[42]	giv[39]|new[42]	_	_
11-17	849-859	sanitation	place[39]|substance[42]	giv[39]|new[42]	_	_
11-18	860-861	,	place[39]	giv[39]	_	_
11-19	862-865	and	place[39]	giv[39]	_	_
11-20	866-870	poor	place[39]|abstract[44]	giv[39]|new[44]	_	_
11-21	871-878	dietary	place[39]|abstract|abstract[44]	giv[39]|new|new[44]	_	_
11-22	879-885	status	place[39]|abstract[44]	giv[39]|new[44]	_	_
11-23	886-887	.	_	_	_	_

#Text=The infection is caused by fecal – oral transmission and initiated by the ingestion of infectious cysts from contaminated water or through person-to-person contact .
12-1	888-891	The	abstract[45]	giv[45]	coref	14-4[60_45]
12-2	892-901	infection	abstract[45]	giv[45]	_	_
12-3	902-904	is	_	_	_	_
12-4	905-911	caused	_	_	_	_
12-5	912-914	by	_	_	_	_
12-6	915-920	fecal	substance	new	_	_
12-7	921-922	–	_	_	_	_
12-8	923-927	oral	abstract[47]	new[47]	_	_
12-9	928-940	transmission	abstract[47]	new[47]	_	_
12-10	941-944	and	_	_	_	_
12-11	945-954	initiated	_	_	_	_
12-12	955-957	by	_	_	_	_
12-13	958-961	the	event[48]	new[48]	_	_
12-14	962-971	ingestion	event[48]	new[48]	_	_
12-15	972-974	of	event[48]	new[48]	_	_
12-16	975-985	infectious	event[48]|object[49]	new[48]|new[49]	_	_
12-17	986-991	cysts	event[48]|object[49]	new[48]|new[49]	_	_
12-18	992-996	from	event[48]|object[49]	new[48]|new[49]	_	_
12-19	997-1009	contaminated	event[48]|object[49]|substance[50]	new[48]|new[49]|giv[50]	_	_
12-20	1010-1015	water	event[48]|object[49]|substance[50]	new[48]|new[49]|giv[50]	_	_
12-21	1016-1018	or	_	_	_	_
12-22	1019-1026	through	_	_	_	_
12-23	1027-1043	person-to-person	abstract[51]	new[51]	_	_
12-24	1044-1051	contact	abstract[51]	new[51]	_	_
12-25	1052-1053	.	_	_	_	_

#Text=After excystation , flagellated trophozoites colonize the upper small intestine , where they attach to the epithelial lining but do not invade the mucosa .
13-1	1054-1059	After	_	_	_	_
13-2	1060-1071	excystation	event	new	_	_
13-3	1072-1073	,	_	_	_	_
13-4	1074-1085	flagellated	animal[53]	new[53]	ana	13-13[0_53]
13-5	1086-1098	trophozoites	animal[53]	new[53]	_	_
13-6	1099-1107	colonize	_	_	_	_
13-7	1108-1111	the	place[54]	new[54]	_	_
13-8	1112-1117	upper	place[54]	new[54]	_	_
13-9	1118-1123	small	place[54]	new[54]	_	_
13-10	1124-1133	intestine	place[54]	new[54]	_	_
13-11	1134-1135	,	_	_	_	_
13-12	1136-1141	where	_	_	_	_
13-13	1142-1146	they	animal	giv	_	_
13-14	1147-1153	attach	_	_	_	_
13-15	1154-1156	to	_	_	_	_
13-16	1157-1160	the	place[56]	new[56]	_	_
13-17	1161-1171	epithelial	place[56]	new[56]	_	_
13-18	1172-1178	lining	place[56]	new[56]	_	_
13-19	1179-1182	but	_	_	_	_
13-20	1183-1185	do	_	_	_	_
13-21	1186-1189	not	_	_	_	_
13-22	1190-1196	invade	_	_	_	_
13-23	1197-1200	the	object[57]	new[57]	_	_
13-24	1201-1207	mucosa	object[57]	new[57]	_	_
13-25	1208-1209	.	_	_	_	_

#Text=The duration of Giardia infection is variable ; however , chronic infection and reinfection commonly occur .
14-1	1210-1213	The	abstract[58]	new[58]	_	_
14-2	1214-1222	duration	abstract[58]	new[58]	_	_
14-3	1223-1225	of	abstract[58]	new[58]	_	_
14-4	1226-1233	Giardia	abstract[58]|object|abstract[60]	new[58]|giv|giv[60]	coref|coref|coref|coref	14-11[61_60]|18-6|14-11[61_60]|18-6
14-5	1234-1243	infection	abstract[58]|abstract[60]	new[58]|giv[60]	_	_
14-6	1244-1246	is	_	_	_	_
14-7	1247-1255	variable	_	_	_	_
14-8	1256-1257	;	_	_	_	_
14-9	1258-1265	however	_	_	_	_
14-10	1266-1267	,	_	_	_	_
14-11	1268-1275	chronic	abstract[61]	giv[61]	coref	15-10[0_61]
14-12	1276-1285	infection	abstract[61]	giv[61]	_	_
14-13	1286-1289	and	_	_	_	_
14-14	1290-1301	reinfection	event	new	_	_
14-15	1302-1310	commonly	_	_	_	_
14-16	1311-1316	occur	_	_	_	_
14-17	1317-1318	.	_	_	_	_

#Text=Approximately 50 % of the symptoms classically associated with giardiasis are asymptomatic including diarrhea , abdominal pain , nausea , vomiting , and anorexia .
15-1	1319-1332	Approximately	quantity[63]	new[63]	_	_
15-2	1333-1335	50	quantity[63]	new[63]	_	_
15-3	1336-1337	%	quantity[63]	new[63]	_	_
15-4	1338-1340	of	quantity[63]	new[63]	_	_
15-5	1341-1344	the	quantity[63]|abstract[64]	new[63]|new[64]	_	_
15-6	1345-1353	symptoms	quantity[63]|abstract[64]	new[63]|new[64]	_	_
15-7	1354-1365	classically	_	_	_	_
15-8	1366-1376	associated	_	_	_	_
15-9	1377-1381	with	_	_	_	_
15-10	1382-1392	giardiasis	abstract	giv	coref	18-35[85_0]
15-11	1393-1396	are	_	_	_	_
15-12	1397-1409	asymptomatic	_	_	_	_
15-13	1410-1419	including	_	_	_	_
15-14	1420-1428	diarrhea	abstract	new	coref	26-18
15-15	1429-1430	,	_	_	_	_
15-16	1431-1440	abdominal	abstract[67]	new[67]	coref	26-15[133_67]
15-17	1441-1445	pain	abstract[67]	new[67]	_	_
15-18	1446-1447	,	_	_	_	_
15-19	1448-1454	nausea	_	_	_	_
15-20	1455-1456	,	_	_	_	_
15-21	1457-1465	vomiting	abstract	new	_	_
15-22	1466-1467	,	_	_	_	_
15-23	1468-1471	and	_	_	_	_
15-24	1472-1480	anorexia	abstract	new	_	_
15-25	1481-1482	.	_	_	_	_

#Text=However , infected individuals can also develop extraintestinal and postinfectious complications .
16-1	1483-1490	However	_	_	_	_
16-2	1491-1492	,	_	_	_	_
16-3	1493-1501	infected	person[70]	new[70]	_	_
16-4	1502-1513	individuals	person[70]	new[70]	_	_
16-5	1514-1517	can	_	_	_	_
16-6	1518-1522	also	_	_	_	_
16-7	1523-1530	develop	abstract	new	coref|none	30-6[160_0]|16-7[0_160]
16-8	1531-1546	extraintestinal	abstract[71]	new[71]	_	_
16-9	1547-1550	and	abstract[71]	new[71]	_	_
16-10	1551-1565	postinfectious	abstract[71]	new[71]	_	_
16-11	1566-1579	complications	abstract[71]	new[71]	_	_
16-12	1580-1581	.	_	_	_	_

#Text=Chronic extraintestinal sequelae may affect the joints , skin , eyes , and central nervous system , but the underlying mechanisms are unknown .
17-1	1582-1589	Chronic	abstract[72]	new[72]	_	_
17-2	1590-1605	extraintestinal	abstract[72]	new[72]	_	_
17-3	1606-1614	sequelae	abstract[72]	new[72]	_	_
17-4	1615-1618	may	_	_	_	_
17-5	1619-1625	affect	_	_	_	_
17-6	1626-1629	the	object[73]	new[73]	_	_
17-7	1630-1636	joints	object[73]	new[73]	_	_
17-8	1637-1638	,	_	_	_	_
17-9	1639-1643	skin	object	new	_	_
17-10	1644-1645	,	_	_	_	_
17-11	1646-1650	eyes	object	new	_	_
17-12	1651-1652	,	_	_	_	_
17-13	1653-1656	and	_	_	_	_
17-14	1657-1664	central	place[76]	new[76]	_	_
17-15	1665-1672	nervous	place[76]	new[76]	_	_
17-16	1673-1679	system	place[76]	new[76]	_	_
17-17	1680-1681	,	_	_	_	_
17-18	1682-1685	but	_	_	_	_
17-19	1686-1689	the	abstract[77]	new[77]	_	_
17-20	1690-1700	underlying	abstract[77]	new[77]	_	_
17-21	1701-1711	mechanisms	abstract[77]	new[77]	_	_
17-22	1712-1715	are	_	_	_	_
17-23	1716-1723	unknown	_	_	_	_
17-24	1724-1725	.	_	_	_	_

#Text=According to research data , Giardia has eight distinct genetic assemblages labelled as assemblage “ A ” through “ H ” , and assemblages “ A ” and “ B ” are responsible for infection in humans .
18-1	1726-1735	According	_	_	_	_
18-2	1736-1738	to	_	_	_	_
18-3	1739-1747	research	abstract|abstract[79]	new|new[79]	coref|coref	30-3|30-3
18-4	1748-1752	data	abstract[79]	new[79]	_	_
18-5	1753-1754	,	_	_	_	_
18-6	1755-1762	Giardia	animal	giv	coref	23-23
18-7	1763-1766	has	_	_	_	_
18-8	1767-1772	eight	abstract[81]	new[81]	_	_
18-9	1773-1781	distinct	abstract[81]	new[81]	_	_
18-10	1782-1789	genetic	abstract[81]	new[81]	_	_
18-11	1790-1801	assemblages	abstract[81]	new[81]	_	_
18-12	1802-1810	labelled	_	_	_	_
18-13	1811-1813	as	_	_	_	_
18-14	1814-1824	assemblage	_	_	_	_
18-15	1825-1826	“	person[82]	new[82]	_	_
18-16	1827-1828	A	person[82]	new[82]	_	_
18-17	1829-1830	”	person[82]	new[82]	_	_
18-18	1831-1838	through	person[82]	new[82]	_	_
18-19	1839-1840	“	person[82]	new[82]	_	_
18-20	1841-1842	H	person[82]	new[82]	_	_
18-21	1843-1844	”	person[82]	new[82]	_	_
18-22	1845-1846	,	_	_	_	_
18-23	1847-1850	and	_	_	_	_
18-24	1851-1862	assemblages	object[83]	new[83]	_	_
18-25	1863-1864	“	object[83]	new[83]	_	_
18-26	1865-1866	A	object[83]	new[83]	_	_
18-27	1867-1868	”	object[83]	new[83]	_	_
18-28	1869-1872	and	_	_	_	_
18-29	1873-1874	“	_	_	_	_
18-30	1875-1876	B	place	new	_	_
18-31	1877-1878	”	_	_	_	_
18-32	1879-1882	are	_	_	_	_
18-33	1883-1894	responsible	_	_	_	_
18-34	1895-1898	for	_	_	_	_
18-35	1899-1908	infection	abstract[85]	giv[85]	coref	19-12[0_85]
18-36	1909-1911	in	abstract[85]	giv[85]	_	_
18-37	1912-1918	humans	abstract[85]|person	giv[85]|new	_	_
18-38	1919-1920	.	_	_	_	_

#Text=Three classes of drugs are currently used for the treatment of giardiasis : metronidazole , mepacrine analogs , and nitrofurans , such as furazolidone (
19-1	1921-1926	Three	person[87]	new[87]	_	_
19-2	1927-1934	classes	person[87]	new[87]	_	_
19-3	1935-1937	of	person[87]	new[87]	_	_
19-4	1938-1943	drugs	person[87]|substance	new[87]|new	coref	27-22[143_0]
19-5	1944-1947	are	_	_	_	_
19-6	1948-1957	currently	_	_	_	_
19-7	1958-1962	used	_	_	_	_
19-8	1963-1966	for	_	_	_	_
19-9	1967-1970	the	abstract[89]	new[89]	_	_
19-10	1971-1980	treatment	abstract[89]	new[89]	_	_
19-11	1981-1983	of	abstract[89]	new[89]	_	_
19-12	1984-1994	giardiasis	abstract[89]|abstract	new[89]|giv	coref	22-12
19-13	1995-1996	:	abstract[89]	new[89]	_	_
19-14	1997-2010	metronidazole	abstract[89]|substance	new[89]|new	coref	22-1
19-15	2011-2012	,	abstract[89]	new[89]	_	_
19-16	2013-2022	mepacrine	abstract[89]|substance[92]	new[89]|new[92]	_	_
19-17	2023-2030	analogs	abstract[89]|substance[92]	new[89]|new[92]	_	_
19-18	2031-2032	,	abstract[89]	new[89]	_	_
19-19	2033-2036	and	abstract[89]	new[89]	_	_
19-20	2037-2048	nitrofurans	abstract[89]|substance[93]	new[89]|new[93]	_	_
19-21	2049-2050	,	abstract[89]|substance[93]	new[89]|new[93]	_	_
19-22	2051-2055	such	abstract[89]|substance[93]	new[89]|new[93]	_	_
19-23	2056-2058	as	abstract[89]|substance[93]	new[89]|new[93]	_	_
19-24	2059-2071	furazolidone	abstract[89]|substance[93]|substance	new[89]|new[93]|new	coref	28-1
19-25	2072-2073	(	_	_	_	_

#Text=Figure 1
20-1	2074-2080	Figure	object[95]	new[95]	_	_
20-2	2081-2082	1	object[95]	new[95]	_	_

#Text=) .
21-1	2083-2084	)	_	_	_	_
21-2	2085-2086	.	_	_	_	_

#Text=Metronidazole is the most widely used drug for the treatment of giardiasis globally and it is generally effective and well-tolerated .
22-1	2087-2100	Metronidazole	substance	giv	coref	22-3[97_0]
22-2	2101-2103	is	_	_	_	_
22-3	2104-2107	the	substance[97]	giv[97]	ana	22-15[0_97]
22-4	2108-2112	most	substance[97]	giv[97]	_	_
22-5	2113-2119	widely	substance[97]	giv[97]	_	_
22-6	2120-2124	used	substance[97]	giv[97]	_	_
22-7	2125-2129	drug	substance[97]	giv[97]	_	_
22-8	2130-2133	for	substance[97]	giv[97]	_	_
22-9	2134-2137	the	substance[97]|abstract[98]	giv[97]|new[98]	coref	24-17[124_98]
22-10	2138-2147	treatment	substance[97]|abstract[98]	giv[97]|new[98]	_	_
22-11	2148-2150	of	substance[97]|abstract[98]	giv[97]|new[98]	_	_
22-12	2151-2161	giardiasis	substance[97]|abstract[98]|abstract	giv[97]|new[98]|giv	coref	23-23[108_0]
22-13	2162-2170	globally	_	_	_	_
22-14	2171-2174	and	_	_	_	_
22-15	2175-2177	it	substance	giv	coref	23-17[105_0]
22-16	2178-2180	is	_	_	_	_
22-17	2181-2190	generally	_	_	_	_
22-18	2191-2200	effective	_	_	_	_
22-19	2201-2204	and	_	_	_	_
22-20	2205-2219	well-tolerated	_	_	_	_
22-21	2220-2221	.	_	_	_	_

#Text=However , the United States Food and Drug Administration ( FDA ) has not yet approved this drug for the treatment of Giardia infection because of its toxicity and major side effects , such as seizures , ataxia , peripheral neuropathy , transient myopia , gastric mucosal irritation , sperm damage , and hematuria .
23-1	2222-2229	However	_	_	_	_
23-2	2230-2231	,	_	_	_	_
23-3	2232-2235	the	object[102]	new[102]	_	_
23-4	2236-2242	United	place[101]|object[102]	new[101]|new[102]	coref	27-7[139_101]
23-5	2243-2249	States	place[101]|object[102]	new[101]|new[102]	_	_
23-6	2250-2254	Food	object[102]	new[102]	_	_
23-7	2255-2258	and	_	_	_	_
23-8	2259-2263	Drug	organization[103]	new[103]	appos	23-11[0_103]
23-9	2264-2278	Administration	organization[103]	new[103]	_	_
23-10	2279-2280	(	_	_	_	_
23-11	2281-2284	FDA	organization	giv	coref	24-14[123_0]
23-12	2285-2286	)	_	_	_	_
23-13	2287-2290	has	_	_	_	_
23-14	2291-2294	not	_	_	_	_
23-15	2295-2298	yet	_	_	_	_
23-16	2299-2307	approved	_	_	_	_
23-17	2308-2312	this	substance[105]	giv[105]	coref	29-7[158_105]
23-18	2313-2317	drug	substance[105]	giv[105]	_	_
23-19	2318-2321	for	substance[105]	giv[105]	_	_
23-20	2322-2325	the	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-21	2326-2335	treatment	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-22	2336-2338	of	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-23	2339-2346	Giardia	substance[105]|abstract[106]|object|abstract[108]	giv[105]|new[106]|giv|giv[108]	coref|coref	24-20[0_108]|24-20[0_108]
23-24	2347-2356	infection	substance[105]|abstract[106]|abstract[108]	giv[105]|new[106]|giv[108]	_	_
23-25	2357-2364	because	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-26	2365-2367	of	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-27	2368-2371	its	substance[105]|abstract[106]|abstract[109]	giv[105]|new[106]|new[109]	_	_
23-28	2372-2380	toxicity	substance[105]|abstract[106]|abstract[109]	giv[105]|new[106]|new[109]	_	_
23-29	2381-2384	and	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-30	2385-2390	major	substance[105]|abstract[106]|abstract[110]	giv[105]|new[106]|new[110]	coref	26-10[132_110]
23-31	2391-2395	side	substance[105]|abstract[106]|abstract[110]	giv[105]|new[106]|new[110]	_	_
23-32	2396-2403	effects	substance[105]|abstract[106]|abstract[110]	giv[105]|new[106]|new[110]	_	_
23-33	2404-2405	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-34	2406-2410	such	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-35	2411-2413	as	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-36	2414-2422	seizures	substance[105]|abstract[106]|event	giv[105]|new[106]|new	_	_
23-37	2423-2424	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-38	2425-2431	ataxia	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-39	2432-2433	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-40	2434-2444	peripheral	substance[105]|abstract[106]|object[112]	giv[105]|new[106]|new[112]	_	_
23-41	2445-2455	neuropathy	substance[105]|abstract[106]|object[112]	giv[105]|new[106]|new[112]	_	_
23-42	2456-2457	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-43	2458-2467	transient	substance[105]|abstract[106]|abstract[113]	giv[105]|new[106]|new[113]	_	_
23-44	2468-2474	myopia	substance[105]|abstract[106]|abstract[113]	giv[105]|new[106]|new[113]	_	_
23-45	2475-2476	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-46	2477-2484	gastric	substance[105]|abstract[106]|abstract|abstract[115]	giv[105]|new[106]|new|new[115]	_	_
23-47	2485-2492	mucosal	substance[105]|abstract[106]|abstract[115]	giv[105]|new[106]|new[115]	_	_
23-48	2493-2503	irritation	substance[105]|abstract[106]|abstract[115]	giv[105]|new[106]|new[115]	_	_
23-49	2504-2505	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-50	2506-2511	sperm	substance[105]|abstract[106]|substance|abstract[117]	giv[105]|new[106]|new|new[117]	_	_
23-51	2512-2518	damage	substance[105]|abstract[106]|abstract[117]	giv[105]|new[106]|new[117]	_	_
23-52	2519-2520	,	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-53	2521-2524	and	substance[105]|abstract[106]	giv[105]|new[106]	_	_
23-54	2525-2534	hematuria	substance[105]|abstract[106]|abstract	giv[105]|new[106]|new	_	_
23-55	2535-2536	.	_	_	_	_

#Text=Tinidazole is an N1-position modified 5-nitro imidazole , which has been approved by the FDA for the treatment of giardiasis .
24-1	2537-2547	Tinidazole	substance	new	coref	24-3[122_0]
24-2	2548-2550	is	_	_	_	_
24-3	2551-2553	an	substance[122]	giv[122]	_	_
24-4	2554-2565	N1-position	abstract|substance[122]	new|giv[122]	_	_
24-5	2566-2574	modified	substance[122]	giv[122]	_	_
24-6	2575-2582	5-nitro	organization|substance[122]	new|giv[122]	_	_
24-7	2583-2592	imidazole	substance[122]	giv[122]	_	_
24-8	2593-2594	,	_	_	_	_
24-9	2595-2600	which	_	_	_	_
24-10	2601-2604	has	_	_	_	_
24-11	2605-2609	been	_	_	_	_
24-12	2610-2618	approved	_	_	_	_
24-13	2619-2621	by	_	_	_	_
24-14	2622-2625	the	organization[123]	giv[123]	_	_
24-15	2626-2629	FDA	organization[123]	giv[123]	_	_
24-16	2630-2633	for	_	_	_	_
24-17	2634-2637	the	abstract[124]	giv[124]	coref	30-14[162_124]
24-18	2638-2647	treatment	abstract[124]	giv[124]	_	_
24-19	2648-2650	of	abstract[124]	giv[124]	_	_
24-20	2651-2661	giardiasis	abstract[124]|abstract	giv[124]|giv	coref	30-17
24-21	2662-2663	.	_	_	_	_

#Text=Nitazoxanide ( NTZ ) belongs to an emerging class of 5-nitrothiazole compounds with potential antigiardial activity .
25-1	2664-2676	Nitazoxanide	substance	new	_	_
25-2	2677-2678	(	_	_	_	_
25-3	2679-2682	NTZ	place	new	coref	26-4
25-4	2683-2684	)	_	_	_	_
25-5	2685-2692	belongs	_	_	_	_
25-6	2693-2695	to	_	_	_	_
25-7	2696-2698	an	abstract[128]	new[128]	_	_
25-8	2699-2707	emerging	abstract[128]	new[128]	_	_
25-9	2708-2713	class	abstract[128]	new[128]	_	_
25-10	2714-2716	of	abstract[128]	new[128]	_	_
25-11	2717-2732	5-nitrothiazole	abstract[128]|substance[129]	new[128]|new[129]	_	_
25-12	2733-2742	compounds	abstract[128]|substance[129]	new[128]|new[129]	_	_
25-13	2743-2747	with	abstract[128]|substance[129]	new[128]|new[129]	_	_
25-14	2748-2757	potential	abstract[128]|substance[129]|abstract[130]	new[128]|new[129]|new[130]	_	_
25-15	2758-2770	antigiardial	abstract[128]|substance[129]|abstract[130]	new[128]|new[129]|new[130]	_	_
25-16	2771-2779	activity	abstract[128]|substance[129]|abstract[130]	new[128]|new[129]|new[130]	_	_
25-17	2780-2781	.	_	_	_	_

#Text=However , although NTZ is generally well tolerated , some adverse effects such as abdominal pain , diarrhea , and nausea limit the safe use for human beings .
26-1	2782-2789	However	_	_	_	_
26-2	2790-2791	,	_	_	_	_
26-3	2792-2800	although	_	_	_	_
26-4	2801-2804	NTZ	substance	giv	_	_
26-5	2805-2807	is	_	_	_	_
26-6	2808-2817	generally	_	_	_	_
26-7	2818-2822	well	_	_	_	_
26-8	2823-2832	tolerated	_	_	_	_
26-9	2833-2834	,	_	_	_	_
26-10	2835-2839	some	abstract[132]	giv[132]	coref	28-4[146_132]
26-11	2840-2847	adverse	abstract[132]	giv[132]	_	_
26-12	2848-2855	effects	abstract[132]	giv[132]	_	_
26-13	2856-2860	such	abstract[132]	giv[132]	_	_
26-14	2861-2863	as	abstract[132]	giv[132]	_	_
26-15	2864-2873	abdominal	abstract[132]|abstract[133]	giv[132]|giv[133]	_	_
26-16	2874-2878	pain	abstract[132]|abstract[133]	giv[132]|giv[133]	_	_
26-17	2879-2880	,	abstract[132]	giv[132]	_	_
26-18	2881-2889	diarrhea	abstract[132]|abstract	giv[132]|giv	_	_
26-19	2890-2891	,	abstract[132]	giv[132]	_	_
26-20	2892-2895	and	abstract[132]	giv[132]	_	_
26-21	2896-2902	nausea	abstract[132]|event	giv[132]|new	_	_
26-22	2903-2908	limit	abstract[132]	giv[132]	_	_
26-23	2909-2912	the	abstract[136]	new[136]	ana	27-12[0_136]
26-24	2913-2917	safe	abstract[136]	new[136]	_	_
26-25	2918-2921	use	abstract[136]	new[136]	_	_
26-26	2922-2925	for	abstract[136]	new[136]	_	_
26-27	2926-2931	human	abstract[136]|person[137]	new[136]|giv[137]	_	_
26-28	2932-2938	beings	abstract[136]|person[137]	new[136]|giv[137]	_	_
26-29	2939-2940	.	_	_	_	_

#Text=Mepacrine is no longer available in the United States , and it is being replaced in most of its applications with safer and more specific drugs .
27-1	2941-2950	Mepacrine	substance	new	_	_
27-2	2951-2953	is	_	_	_	_
27-3	2954-2956	no	_	_	_	_
27-4	2957-2963	longer	_	_	_	_
27-5	2964-2973	available	_	_	_	_
27-6	2974-2976	in	_	_	_	_
27-7	2977-2980	the	place[139]	giv[139]	_	_
27-8	2981-2987	United	place[139]	giv[139]	_	_
27-9	2988-2994	States	place[139]	giv[139]	_	_
27-10	2995-2996	,	_	_	_	_
27-11	2997-3000	and	_	_	_	_
27-12	3001-3003	it	abstract	giv	ana	27-19
27-13	3004-3006	is	_	_	_	_
27-14	3007-3012	being	_	_	_	_
27-15	3013-3021	replaced	_	_	_	_
27-16	3022-3024	in	_	_	_	_
27-17	3025-3029	most	abstract[142]	new[142]	_	_
27-18	3030-3032	of	abstract[142]	new[142]	_	_
27-19	3033-3036	its	abstract|abstract[142]	giv|new[142]	_	_
27-20	3037-3049	applications	abstract[142]	new[142]	_	_
27-21	3050-3054	with	abstract[142]	new[142]	_	_
27-22	3055-3060	safer	abstract[142]|substance[143]	new[142]|giv[143]	coref	30-11[161_143]
27-23	3061-3064	and	abstract[142]|substance[143]	new[142]|giv[143]	_	_
27-24	3065-3069	more	abstract[142]|substance[143]	new[142]|giv[143]	_	_
27-25	3070-3078	specific	abstract[142]|substance[143]	new[142]|giv[143]	_	_
27-26	3079-3084	drugs	abstract[142]|substance[143]	new[142]|giv[143]	_	_
27-27	3085-3086	.	_	_	_	_

#Text=Furazolidone also has serious side effects , such as gastrointestinal disturbances , hemolytic anemia , disulfiram-like reactions to alcohol , and hypersensitivity reactions , as well as evidence of tumorigenicity in rodent studies .
28-1	3087-3099	Furazolidone	substance	giv	_	_
28-2	3100-3104	also	_	_	_	_
28-3	3105-3108	has	_	_	_	_
28-4	3109-3116	serious	abstract[146]	giv[146]	_	_
28-5	3117-3121	side	abstract|abstract[146]	new|giv[146]	_	_
28-6	3122-3129	effects	abstract[146]	giv[146]	_	_
28-7	3130-3131	,	abstract[146]	giv[146]	_	_
28-8	3132-3136	such	abstract[146]	giv[146]	_	_
28-9	3137-3139	as	abstract[146]	giv[146]	_	_
28-10	3140-3156	gastrointestinal	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
28-11	3157-3169	disturbances	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
28-12	3170-3171	,	abstract[146]	giv[146]	_	_
28-13	3172-3181	hemolytic	abstract[146]|abstract[148]	giv[146]|new[148]	_	_
28-14	3182-3188	anemia	abstract[146]|abstract[148]	giv[146]|new[148]	_	_
28-15	3189-3190	,	abstract[146]	giv[146]	_	_
28-16	3191-3206	disulfiram-like	abstract[146]|event[149]	giv[146]|new[149]	_	_
28-17	3207-3216	reactions	abstract[146]|event[149]	giv[146]|new[149]	_	_
28-18	3217-3219	to	abstract[146]|event[149]	giv[146]|new[149]	_	_
28-19	3220-3227	alcohol	abstract[146]|event[149]|substance	giv[146]|new[149]|new	_	_
28-20	3228-3229	,	abstract[146]	giv[146]	_	_
28-21	3230-3233	and	abstract[146]	giv[146]	_	_
28-22	3234-3250	hypersensitivity	abstract[146]|abstract|abstract[152]	giv[146]|new|new[152]	_	_
28-23	3251-3260	reactions	abstract[146]|abstract[152]	giv[146]|new[152]	_	_
28-24	3261-3262	,	abstract[146]	giv[146]	_	_
28-25	3263-3265	as	abstract[146]	giv[146]	_	_
28-26	3266-3270	well	abstract[146]	giv[146]	_	_
28-27	3271-3273	as	abstract[146]	giv[146]	_	_
28-28	3274-3282	evidence	abstract[146]|abstract[153]	giv[146]|new[153]	_	_
28-29	3283-3285	of	abstract[146]|abstract[153]	giv[146]|new[153]	_	_
28-30	3286-3300	tumorigenicity	abstract[146]|abstract[153]|abstract[154]	giv[146]|new[153]|new[154]	_	_
28-31	3301-3303	in	abstract[146]|abstract[153]|abstract[154]	giv[146]|new[153]|new[154]	_	_
28-32	3304-3310	rodent	abstract[146]|abstract[153]|abstract[154]|animal|abstract[156]	giv[146]|new[153]|new[154]|new|new[156]	_	_
28-33	3311-3318	studies	abstract[146]|abstract[153]|abstract[154]|abstract[156]	giv[146]|new[153]|new[154]|new[156]	_	_
28-34	3319-3320	.	_	_	_	_

#Text=Furthermore , G. lamblia resistance to this drug has also been reported .
29-1	3321-3332	Furthermore	_	_	_	_
29-2	3333-3334	,	_	_	_	_
29-3	3335-3337	G.	abstract[157]	new[157]	_	_
29-4	3338-3345	lamblia	abstract[157]	new[157]	_	_
29-5	3346-3356	resistance	abstract[157]	new[157]	_	_
29-6	3357-3359	to	abstract[157]	new[157]	_	_
29-7	3360-3364	this	abstract[157]|substance[158]	new[157]|giv[158]	_	_
29-8	3365-3369	drug	abstract[157]|substance[158]	new[157]|giv[158]	_	_
29-9	3370-3373	has	_	_	_	_
29-10	3374-3378	also	_	_	_	_
29-11	3379-3383	been	_	_	_	_
29-12	3384-3392	reported	_	_	_	_
29-13	3393-3394	.	_	_	_	_

#Text=Therefore , research focusing on the development of novel , alternative drugs for the treatment of giardiasis is highly desirable .
30-1	3395-3404	Therefore	_	_	_	_
30-2	3405-3406	,	_	_	_	_
30-3	3407-3415	research	abstract	giv	_	_
30-4	3416-3424	focusing	_	_	_	_
30-5	3425-3427	on	_	_	_	_
30-6	3428-3431	the	abstract[160]	new[160]	_	_
30-7	3432-3443	development	abstract[160]	new[160]	_	_
30-8	3444-3446	of	abstract[160]	new[160]	_	_
30-9	3447-3452	novel	abstract[160]	new[160]	_	_
30-10	3453-3454	,	_	_	_	_
30-11	3455-3466	alternative	substance[161]	giv[161]	_	_
30-12	3467-3472	drugs	substance[161]	giv[161]	_	_
30-13	3473-3476	for	substance[161]	giv[161]	_	_
30-14	3477-3480	the	substance[161]|abstract[162]	giv[161]|giv[162]	coref	31-16[168_162]
30-15	3481-3490	treatment	substance[161]|abstract[162]	giv[161]|giv[162]	_	_
30-16	3491-3493	of	substance[161]|abstract[162]	giv[161]|giv[162]	_	_
30-17	3494-3504	giardiasis	substance[161]|abstract[162]|abstract	giv[161]|giv[162]|giv	coref	31-19
30-18	3505-3507	is	_	_	_	_
30-19	3508-3514	highly	_	_	_	_
30-20	3515-3524	desirable	_	_	_	_
30-21	3525-3526	.	_	_	_	_

#Text=In view of these considerations , researchers have designed and synthesized some novel molecules for the treatment of giardiasis , their results are summarized in Table 1 .
31-1	3527-3529	In	_	_	_	_
31-2	3530-3534	view	abstract[164]	new[164]	_	_
31-3	3535-3537	of	abstract[164]	new[164]	_	_
31-4	3538-3543	these	abstract[164]|abstract[165]	new[164]|new[165]	_	_
31-5	3544-3558	considerations	abstract[164]|abstract[165]	new[164]|new[165]	_	_
31-6	3559-3560	,	_	_	_	_
31-7	3561-3572	researchers	person	new	ana	31-21
31-8	3573-3577	have	_	_	_	_
31-9	3578-3586	designed	_	_	_	_
31-10	3587-3590	and	_	_	_	_
31-11	3591-3602	synthesized	_	_	_	_
31-12	3603-3607	some	substance[167]	new[167]	_	_
31-13	3608-3613	novel	substance[167]	new[167]	_	_
31-14	3614-3623	molecules	substance[167]	new[167]	_	_
31-15	3624-3627	for	substance[167]	new[167]	_	_
31-16	3628-3631	the	substance[167]|abstract[168]	new[167]|giv[168]	_	_
31-17	3632-3641	treatment	substance[167]|abstract[168]	new[167]|giv[168]	_	_
31-18	3642-3644	of	substance[167]|abstract[168]	new[167]|giv[168]	_	_
31-19	3645-3655	giardiasis	substance[167]|abstract[168]|abstract	new[167]|giv[168]|giv	_	_
31-20	3656-3657	,	_	_	_	_
31-21	3658-3663	their	person|abstract[171]	giv|new[171]	_	_
31-22	3664-3671	results	abstract[171]	new[171]	_	_
31-23	3672-3675	are	_	_	_	_
31-24	3676-3686	summarized	_	_	_	_
31-25	3687-3689	in	_	_	_	_
31-26	3690-3695	Table	object[172]	new[172]	_	_
31-27	3696-3697	1	object[172]	new[172]	_	_
31-28	3698-3699	.	_	_	_	_
